Spinal Muscular Atrophy Trial, Recruiting (NCT06955897)

Spinal Muscular Atrophy Trial, Recruiting NCT06955897 Sponsor: Columbia University Condition: Spinal Muscular Atrophy

Printed from Voxsanity (voxsanity.com.au) — NCT06955897 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Spinal Muscular Atrophy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with spinal muscular atrophy (SMA) caused by a problem with the SMN1 gene (either a missing copy or a mutation), regardless of how many copies of the SMN2 gene you have
You are currently taking nusinersen (Spinraza) at a dose of either 12 mg or 28 mg, and your dose has been stable for at least 6 months

Who may not be able to join:

You have had an injury or surgery in the last 3 months that would affect your ability to complete physical tests at the clinic
You are currently taking part in another clinical trial, expanded access program, long-term study registry, or extension study involving an experimental or recently approved medicine
You are currently taking any additional treatments alongside nusinersen that target muscles, the connection between nerves and muscles, or other SMA symptoms (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jacqueline Montes, Pt, EdD, Columbia University

Phone: 3472877093

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06955897

Sponsor: Columbia University

Phase: Not Applicable

Status: Recruiting

Condition: Spinal Muscular Atrophy

Trial contact: 3472877093

More information: https://clinicaltrials.gov/study/NCT06955897

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with spinal muscular atrophy (SMA) caused by a problem with the SMN1 gene (either a missing copy or a mutation), regardless of how many copies of the SMN2 gene you have
You are currently taking nusinersen (Spinraza) at a dose of either 12 mg or 28 mg, and your dose has been stable for at least 6 months

Who may not be able to join:

You have had an injury or surgery in the last 3 months that would affect your ability to complete physical tests at the clinic
You are currently taking part in another clinical trial, expanded access program, long-term study registry, or extension study involving an experimental or recently approved medicine
You are currently taking any additional treatments alongside nusinersen that target muscles, the connection between nerves and muscles, or other SMA symptoms (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Columbia University

Registry

ClinicalTrials.gov

Start date

24 April 2025

Est. completion

7 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

SMA EFFORT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov